Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-09-28FDA Approved: LEVETIRACETAM — Original Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved Hisun Pharmaceuticals USA, Inc.'s original application for a generic levetiracetam product.
-
FDA approval · 2017-09-14FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc.
-
FDA approval · 2017-09-14FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) from UCB, authorizing changes to its labeling.
-
FDA approval · 2017-09-13FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc.
-
FDA approval · 2017-08-14FDA Approved: LEVETIRACETAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application to authorize Aurobindo Pharma Limited to manufacture levetiracetam (generic) in the United States.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-07-26FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
FDA approved Eisai Inc.'s supplemental application for FYCOMPA (perampanel), updating the labeling to reflect the approved change.
-
FDA approval · 2017-06-09FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
FDA approves a supplemental application for levetiracetam by Prasco Laboratories, enabling a generic version to be marketed.
-
FDA approval · 2017-04-24FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam), authorizing the extended-release formulation from UCB, for use in epi…
-
CLINICAL_TRIALS trial_result · 2017-03-09Clinical Trial Update: Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
This entry notes a completed clinical trial evaluating the dosage, efficacy, and safety of perampanel as monotherapy in patients with epilep…
-
FDA approval · 2017-03-07FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc.
-
CLINICAL_TRIALS trial_result · 2017-01-18Clinical Trial Update: A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures [Phase 3]
A Phase 3 double-blind trial evaluating brivaracetam as monotherapy in adults with partial-onset seizures was terminated, with results poste…
-
FDA approval · 2016-12-22FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Division of Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2016-12-05Clinical Trial Update: Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures [Phase 3]
A Phase 3 trial evaluating lamotrigine extended-release added to existing seizure therapies in patients with partial-onset seizures has comp…
-
FDA approval · 2016-11-02FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in an update to its labeling for epilepsy-related …
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures [Phase 3]
Efficacy and safety results from a Phase 3 trial evaluating eslicarbazepine acetate as monotherapy in adults with newly diagnosed partial-on…
-
FDA approval · 2016-09-16FDA Approved: LEVETIRACETAM — Original Application (Mylan Institutional LLC)
FDA approved an original ANDA for levetiracetam from Mylan Institutional LLC, enabling a generic version of the anticonvulsant to reach the …
-
CLINICAL_TRIALS trial_result · 2016-08-11Clinical Trial Update: Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures [Phase 3]
A Phase 3 open-label, randomized, active-controlled study evaluating levetiracetam as monotherapy for partial-onset seizures has completed; …
-
FDA approval · 2016-08-01FDA Approved: LEVETIRACETAM SOLUTION — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for LEVETIRACETAM SOLUTION (levetiracetam) from Chartwell RX, LLC, approving a new solution formulat…
-
FDA approval · 2016-07-18FDA Approved: ZONISAMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for zonisamide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2016-06-21FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for Sabril (vigabatrin) from Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2016-04-29FDA Approved: FYCOMPA — Original Application (Eisai Inc.)
The FDA granted original approval for FYCOMPA (perampanel) from Eisai Inc. for add-on therapy in patients with partial-onset seizures, marki…
-
CLINICAL_TRIALS trial_result · 2016-04-13Clinical Trial Update: A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures [Phase 3]
A Phase 3 double-blind, randomized study evaluating brivaracetam monotherapy for partial-onset seizures in adults was terminated but results…
-
FDA label_change · 2016-04-06FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approved a supplemental application for ZONEGRAN (zonisamide) submitted by Advanz Pharma (US) Corp.
-
FDA label_change · 2016-04-06FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Keppra XR (levetiracetam) from UCB, Inc., resulting in changes to the product labeling. The …
-
FDA approval · 2016-02-26FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., expanding/adjusting its approved labeling for the drug.